Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.35 |
| ▸ | LSS | P48449 | 3/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14352536 | 0.79 | EPAS1 (0.37) | EPAS1LSSPLAUPDGFRACDK5 | |
| Ticlatone SCHEMBL910248 | 0.76 | ALDH1A1 (0.40) | ALOX15EPAS1NPC1CYP1A2CYP3A4 | |
| SCHEMBL13202665 | 0.76 | LSS (0.36) | EPAS1LSSPDGFRACDK5TYRO3 | |
| SCHEMBL14861787 | 0.76 | MIF (0.38) | EPAS1LSSPDPK1JAK2MIF | |
| SCHEMBL20520481 | 0.76 | LSS (0.35) | EPAS1LSSPLAURAB9A | |
| SCHEMBL8484255 | 0.75 | LSS (0.46) | LSSPDPK1ESR2 | |
| SCHEMBL30209249 | 0.74 | RXFP1 (0.41) | LSSPDGFRACDK5TYRO3NPC1 | |
| SCHEMBL260308 | 0.74 | RXFP1 (0.41) | LSSPDGFRACDK5TYRO3NPC1 | |
| SCHEMBL4777702 | 0.73 | DGAT1 (0.39) | LSSPLAUGSK3AGSK3BPDGFRA | |
| SCHEMBL22574465 | 0.72 | ERBB2 (0.34) | EPAS1LSSPDPK1JAK2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | INTERVET INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3810576-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | Intervet International B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020002234-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INTERNATIONAL B.V. (NL) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | SORD, HEXD, SDHA | ALOX15 1159/4885EPAS1 4050/4885LSS 1398/4885 |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | SORD, HEXD, SNRPD1 | ALOX15 1031/4885EPAS1 4028/4885LSS 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.